Compare Neurocrine Biosciences Inc (NBIX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Materials Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| NBIX | XLB | |
|---|---|---|
Market Cap | $14.36B | $7.73B |
Volume | 1,237,180 | 13,681,146 |
Sector | Health | — |
52-Week High | $185.50 | $53.67 |
52-Week Low | $123.10 | $42.23 |
Typical Hold Time | 23 Days | 70 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
XLB trades at $49.43, up 0.92% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent news highlights materials as a potential 'anti-AI' play but questions near-term valuation after recent rebounds.
Outlook remains cautious given technical weakness and sector cyclicality. Investment opportunity exists for long-term infrastructure exposure, but risks include overconcentration in chemicals and potential earnings volatility. Current levels near support at $49 require monitoring for breakdown confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
